ramipril + hydrochlorothiazide + moxonidine

A triple combination of **ramipril**, **hydrochlorothiazide**, and **moxonidine**, used experimentally to treat hypertension, particularly in patients with associated type 2 diabetes mellitus. - **Ramipril** is an angiotensin-converting enzyme (ACE) inhibitor, lowering blood pressure by blocking the formation of angiotensin II, thus relaxing blood vessels. - **Hydrochlorothiazide** is a thiazide diuretic, reducing blood pressure by increasing renal excretion of sodium and water, decreasing blood volume. - **Moxonidine** is a selective imidazoline receptor agonist (primarily the I1-imidazoline receptor in the medulla), reducing central sympathetic outflow and peripheral vascular resistance. This triple combination targets different mechanisms involved in blood pressure regulation and is investigated for synergistic efficacy and improved metabolic profile, especially relevant for hypertensive patients with diabetes[1][3][7]. - There is no evidence that a fixed-dose branded product combining all three is commercially available; rather, this regimen is referenced in clinical studies for patients not achieving blood pressure goals with dual combinations[1][3].